Neurocrine Biosciences, Inc.
US ˙ NasdaqGS ˙ US64125C1099

SecurityNBIX / Neurocrine Biosciences, Inc.
InstitutionMacquarie Group Ltd
Latest Disclosed Ownership11,826 shares
Latest Disclosed Value $ 1,557,957
Macquarie Group Ltd reports 7.31% increase in ownership of NBIX / Neurocrine Biosciences, Inc.

On May 15, 2026 - Macquarie Group Ltd filed a 13F-HR form disclosing ownership of 11,826 shares of Neurocrine Biosciences, Inc. (US:NBIX) valued at $1,557,957 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 11,020 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of 7.31% during the quarter. The current value of the position is $1,952,591 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 11,826 806 7.31 1,558 -0.32 0.0073
2026-02-13 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 11,020 -304,442 -96.51 1,563 -96.47 0.0068
2025-11-13 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 315,462 44,960 16.62 44,284 30.25 0.0517
2025-08-14 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 270,502 39,154 16.92 34,000 32.88 0.0417
2025-08-14 2025-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 231,348 -42,778 -15.61 25,587 -31.62 0.0318
2025-05-15 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 231,348 -42,778 25,587 0.0209
2025-02-14 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 274,126 -218,064 -44.30 37,419 -34.02 0.0454
2024-11-14 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 492,190 221,213 81.64 56,710 52.02 0.0612
2024-08-09 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 270,977 -5,033 -1.82 37,305 -2.00 0.0428
2024-05-14 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 276,010 -52,119 -15.88 38,067 -11.95 0.0432
2024-02-14 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 328,129 69,518 26.88 43,234 48.61 0.0499
2023-11-14 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 258,611 -816 -0.31 29,093 18.93 0.0365
2023-10-27 2023-06-30 13F/A-2 NEUROCRINE BIOSCIENCES COM 64125C109 259,427 -33,183 -11.34 24,464 -17.40 0.0280
2023-10-12 2023-06-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 259,427 -33,183 24,464 0.0246
2023-08-14 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 259,427 -33,183 24,464 0.0248
2023-06-01 2023-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 292,610 7,296 2.56 29,618 -13.09 0.0352
2023-05-15 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 292,610 7,296 29,618 0.0272
2023-02-21 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 285,314 -990 -0.35 34,078 12.06 0.0402
2022-11-14 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 286,304 -6,586 -2.25 30,409 6.51 0.0373
2022-08-17 2022-06-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 292,890 -25,173 -7.91 28,551 -4.25 0.0321
2022-08-15 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 292,890 -25,173 28,551 0.0102
2022-05-16 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 318,063 65,302 25.84 29,818 38.51 0.0227
2022-02-11 2021-12-31 13F Neurocrine Biosciences COM 64125C109 252,761 18,676 7.98 21,528 -4.11 0.0179
2021-11-12 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 234,085 -2,371 -1.00 22,451 -2.44 0.0191
2021-08-13 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 236,456 7,699 3.37 23,012 3.44 0.0189
2021-05-14 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 228,757 -2,783 -1.20 22,247 0.24 0.0315
2021-02-16 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 231,540 -718,601 -75.63 22,194 -75.71 0.0324
2020-11-13 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 950,141 37,532 4.11 91,366 -17.94 0.1547
2020-08-11 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 912,609 677,365 287.94 111,339 446.85 0.1917
2020-05-15 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 235,244 298 0.13 20,360 -19.38 0.0418
2020-03-18 2019-12-31 13F/A-2 NEUROCRINE BIOSCIENCES COM 64125C109 234,946 536 0.23 25,254 19.56 0.0361
2020-02-28 2019-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 234,946 0 25,254 0.0365
2020-02-14 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 234,946 536 25,254 31,691.6298
2019-11-14 2019-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 234,410 -7,272 -3.01 21,122 3.51 0.0354
2019-11-06 2019-06-30 13F/A-2 NEUROCRINE BIOSCIENCES COM 64125C109 241,682 8,278 3.55 20,405 -0.77 0.0344
2019-09-24 2019-06-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 241,682 0 20,405 0.0347
2019-08-14 2019-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 241,682 8,278 20,405
2019-05-15 2019-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 233,404 -38,731 -14.23 20,563 5.81 0.0351
2019-02-15 2018-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 272,135 -453,627 -62.50 19,433 -78.22 0.0376
2018-11-15 2018-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 725,762 -108,387 -12.99 89,232 8.89 0.1454
2019-03-21 2018-06-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 834,149 62,979 8.17 81,947 28.14 0.1413
2018-08-14 2018-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 834,149 62,979 81,947
2018-05-11 2018-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 771,170 61,249 8.63 63,953 16.10 0.1165
2018-02-14 2017-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 709,921 -53,311 -6.98 55,083 17.77 0.0974
2017-11-08 2017-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 763,232 4,535 0.60 46,770 34.01 0.0839
2017-08-14 2017-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 758,697 -17,193 -2.22 34,900 3.88 0.0638
2017-05-15 2017-03-31 13F Neurocrine Biosciences COM 64125C109 775,890 143,825 22.75 33,596 37.35 0.0610
2017-03-30 2016-12-31 13F/A-1 Neurocrine Biosciences COMMON 64125C109 632,065 -273,683 -30.22 24,461 -46.67 0.0468
2017-02-15 2016-12-31 13F Neurocrine Biosciences COMMON 64125C109 632,065 24,461
2016-11-15 2016-09-30 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 905,748 775,748 596.73 45,867 676.22 0.0882
2016-09-14 2016-06-30 13F/A-1 NEUROCRINE BIOSCIENCES COMMON 64125C109 130,000 -1,890 -1.43 5,909 13.29 0.0116
2016-08-15 2016-06-30 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 130,000 5,909
2016-05-16 2016-03-31 13F NEUROCRINE BIOSCIENCES COMMON 64125C109 131,890 131,890 5,216 0.0105
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.